Omega-3 (EPA/DHA)

EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are the two long-chain marine omega-3 fatty acids that account for the cardiovascular, brain-health, and now biological-aging signals in this category. ALA — the plant omega-3 in flaxseed, chia, and walnuts — converts to EPA/DHA poorly in humans (typically under 10%, with negligible yield of DHA) and is not a reliable substitute. The most useful framing: if your dietary EPA+DHA intake is adequate, supplementation is unnecessary; if it isn't, supplementation closes a measurable physiological gap that can be tracked on a single blood test.

Two parallel stories

The literature now runs on two parallel tracks that need to be read together:

• The cardiovascular trial track. Large randomized trials at gram-level doses, looking at heart attacks, strokes, and cardiovascular death. The results here are mixed and have a real safety signal at the top of the dose range.
• The biomarker / longevity track. Observational cohorts and a handful of newer trials anchored on the omega-3 index (the EPA+DHA percentage of red-blood-cell membranes), and on epigenetic age. The signal here is more uniformly positive and dose-responsive — but the outcomes are softer (all-cause mortality, biological-age clocks) than hard events.

Almost all of the practical guidance below sits at the intersection of the two: enough EPA+DHA to put your omega-3 index in the protective range, not so much that you cross into the arrhythmia signal seen in high-dose pharmacological trials.

The cardiovascular trial puzzle

The trial that put high-dose EPA back on the map: ^[1]. Icosapent ethyl (purified EPA, 4 g/day) cut major cardiovascular events by 25% over five years on top of optimal statin therapy. The absolute risk reduction was clinically meaningful — about 4–5 events prevented per 100 high-risk patients treated.

But the field has a puzzle. ^[2] (carboxylic-acid form, 4 g/day), was null for cardiovascular events. Two big differences may explain the discrepancy:

• The molecule. Pure EPA versus an EPA+DHA mix. Some research suggests DHA may partly offset EPA's anti-inflammatory and membrane-stabilising effects.
• The placebo. REDUCE-IT used mineral oil, which raised LDL and CRP in the control group — possibly making the active drug look better by comparison. STRENGTH used corn oil, which is more biologically inert.

The honest read: high-dose purified EPA appears to genuinely reduce events in statin-treated patients with elevated triglycerides. Mixed EPA+DHA at high doses has a less convincing event signal but still improves triglycerides and inflammatory markers, and ^[3] showed modest cardiovascular benefit in the lowest-fish-intake subgroup.

For a healthy midlife adult, this means: regular dietary EPA+DHA is well-supported; low-to-moderate supplemental doses are reasonable if you don't eat fish; very high doses are a prescription-territory decision.

The longevity and biological-aging signal

The newer and arguably more interesting evidence comes from biomarker cohorts and from epigenetic-age trials.

In long-running prospective cohorts, adults with an omega-3 index above roughly 6.8% have lower all-cause mortality than those below it, with the pooled estimate landing at 15–20% relative risk reduction across consortia of more than 40,000 individuals.^[4] The mortality signal is most consistent for cardiovascular death but extends to cancer and non-cardiovascular causes in pooled analyses. The dose-response is non-linear for EPA (largest gain in moving from deficient to sufficient, then plateaus) and more linear for DHA.

The 2025 readout that elevated omega-3 from "cardiovascular nutrient" to "candidate longevity intervention" is the epigenetic-age analysis of ^[5]. One gram per day of algal-derived omega-3 (330 mg EPA + 660 mg DHA) slowed several next-generation methylation clocks — PhenoAge, GrimAge2, and DunedinPACE — by the equivalent of roughly three to four months of biological age over three years. DunedinPACE, which estimates the current rate of aging rather than cumulative age, slowed by about 1%. The effect was additive with vitamin D and a light home-exercise program; neither vitamin D nor exercise alone moved the clocks meaningfully in the same trial. Omega-3 was the load-bearing intervention.

A few honest caveats:

• The clocks are surrogate biomarkers of biological age, not hard outcomes. They predict mortality and disease in cohorts, but a slowed clock in a three-year trial is not the same as a longer life.
• The participants were over 70 — older than the typical longevity-curious 40-something — and most had baseline omega-3 indices below the protective range, leaving more room to improve.
• The clock-slowing dose (1 g/day of EPA+DHA) is well below the high-dose cardiovascular-trial range. The longevity signal does not require — and probably does not benefit from — pushing the dose to 4 g/day.

Mechanistically the case is coherent: EPA and DHA integrate into cell membranes, dampen the chronic low-grade inflammation of aging, shift lipid mediators away from pro-inflammatory prostaglandins toward specialized pro-resolving mediators (resolvins, protectins, maresins), and modulate the same nutrient-sensing axes (AMPK, SIRT1, mTOR, autophagy) targeted by caloric restriction and rapamycin. None of that proves causality on its own, but it makes the clock data less surprising.

Test: the omega-3 index

The most useful single lab in this space is the omega-3 index — the percentage of EPA + DHA in red blood cell membranes:

The 8% threshold corresponds roughly to the upper-quintile cardioprotective range in pooled cohort data; the ~7% threshold marks where most longevity cohort signals start to appear. Roughly 1–2 g/day of combined EPA+DHA over 4–6 months brings most adults into the 8–12% range. People who eat fatty fish two to three times weekly often reach it without supplementation. Athletes and habitual non-fish-eaters routinely test in the 3–4% range — i.e. the bottom of the risk-elevated band — even when they consider their diets healthy.^[6]

The omega-6 to omega-3 ratio

A second framing worth knowing, even though it's less actionable than the omega-3 index itself: the ratio of plasma omega-6 to omega-3 polyunsaturated fats. In a UK Biobank analysis of around 85,000 adults followed for an average of 13 years, the highest-ratio quintile carried roughly 26% higher all-cause mortality, 31% higher cardiovascular mortality, and 14% higher cancer mortality than the lowest-ratio quintile.^[7] Modern Western diets frequently sit at 15:1 or higher, against an evolutionary baseline closer to 1:1 to 5:1.

The practical implication is not to chase a target ratio — that's hard to measure cleanly outside of research labs, and the absolute omega-3 level seems to do most of the work. It is to recognize that raising EPA+DHA is the easier lever than cutting omega-6: seed oils, processed snack foods, and most restaurant cooking deliver large omega-6 loads passively. Adding fish or a supplement shifts the ratio in the right direction without requiring a dietary overhaul.

Brain, mood, and cognition

DHA is the dominant structural fatty acid in the brain; EPA is the active mood-and-inflammation lever. The clinical literature reflects that split.

In broad trials of cognitively healthy older adults, omega-3 supplementation has not moved global cognition reliably. A 2025 systematic review of 19 randomized trials in cognitively unimpaired older adults found no overall effect on global cognition.^[8] The trials are heterogeneous (doses, EPA:DHA ratios, durations, baseline status), and the broad-population effect is consistent with a small, hard-to-detect signal in the average healthy adult.

The picture changes in genetically at-risk subgroups. In the ALFA cohort of middle-aged adults with Alzheimer's risk factors (including APOE-ε4 carriers), higher red-blood-cell DHA was linked to slower cognitive decline on a sensitive composite score over multi-year follow-up. EPA showed no equivalent signal in that cohort — consistent with DHA acting structurally in the neuronal membrane before symptomatic disease.^[9]

For major depressive disorder, supplementation works only when the formulation is heavily EPA-weighted. Meta-analyses converge on a required EPA:DHA ratio of at least 1.5:1, and the strongest signal — in patients with elevated inflammatory markers — has come from ratios closer to 4:1 at total doses above 1 g/day. Mood depression is one of the few clinical indications where the choice of EPA:DHA ratio meaningfully changes the outcome; standard generic fish oils are not the right format.

Practical dosing

• Two or more servings of fatty fish per week (salmon, sardines, mackerel, herring, trout) — supplementation is unnecessary.
• No fish in your diet: 1–2 g/day combined EPA+DHA. This is the band that lifts the omega-3 index into the protective range, matches the DO-HEALTH clock-slowing intervention, and stays below the dose at which arrhythmia signals emerge.
• Athletes and heavy training loads: 2–3 g/day during high-volume blocks. The 2025 International Society of Sports Nutrition position concluded that omega-3 supplementation in the 2–3 g/day range reduces exercise-induced muscle soreness, blunts excess inflammatory cytokines, and is reasonable as a recovery aid given how reliably athletes test below an omega-3 index of 4%.^[10]
• Elevated triglycerides or established cardiovascular disease: higher doses (2–4 g/day combined, or — with a prescriber — icosapent ethyl 4 g/day) may be appropriate.
• Vegetarians and vegans: algae-derived oils provide DHA and increasingly EPA. Pharmacokinetic trials show algal oil non-inferior to fish oil for raising plasma and red-cell omega-3 levels.^[11] Microalgae are also the original biological source — fish accumulate EPA and DHA only by eating algae.

Regulatory ceilings are broadly aligned: the European Food Safety Authority concluded long-term combined EPA+DHA up to 5 g/day is safe for healthy adults, and the US FDA broadly agrees, with a 2 g/day cap on over-the-counter supplement label recommendations.

Form, sourcing, and oxidation

The product-quality question is, for most consumers, where omega-3 supplementation actually goes wrong. Three issues stack: the chemical form, the source, and oxidation.

Form

For most healthy adults, a third-party-tested rTG or ethyl ester product taken with food is adequate. The cost difference between rTG and ethyl ester is usually 2–3×; the absorption difference, with meals, is small.

Sourcing

Wild-caught small forage fish (sardines, anchovies, herring, mackerel) remain the highest-density, lowest-contaminant dietary source. Farmed Atlantic salmon was historically a comparable source but its EPA+DHA content has fallen substantially since the mid-2000s as aquaculture feeds have shifted toward cheaper terrestrial plant oils. Algal oil supplements deliver the same EPA and DHA molecules and bypass both the contaminant and sustainability concerns; recent randomized comparisons find them non-inferior to fish oil for raising blood omega-3 levels.^[12]

Oxidation and freshness

The same carbon-carbon double bonds that make EPA and DHA biologically active also make them chemically fragile. Heat, light, and ambient oxygen during manufacture, transport, and storage produce peroxides and secondary aldehydes that the industry summarizes as the TOTOX (total oxidation) value. An independent analysis of 171 North American over-the-counter omega-3 products found roughly half exceeded voluntary AOCS oxidation thresholds, with flavored and chewable formulations the worst offenders.^[13]

Rancid omega-3 doesn't just lose efficacy; it delivers a load of reactive lipid peroxidation products into the GI tract, plausibly counteracting the anti-inflammatory effect the supplement was supposed to produce.

Practical filters:

• Look for an IFOS, Labdoor, USP, or NSF mark on the bottle. IFOS specifically publishes TOTOX numbers and heavy-metal panels per batch.
• Check for a freshness signal on the certificate of analysis (TOTOX, peroxide value, anisidine value).
• Refrigerate after opening and finish the bottle within a few months.
• Trust your nose. A high-quality oil smells nearly neutral. Strong fishy odour or post-dose fishy reflux is the sensory signature of advanced oxidation, not of "real" fish oil.

The atrial fibrillation paradox

This deserves its own section because two genuinely contradictory-looking lines of evidence coexist.

The trial signal. Several high-dose randomized trials of purified or synthetic omega-3 (mostly ethyl ester, mostly at 1–4 g/day, in older patients with established cardiovascular disease) showed a small but real increase in new-onset atrial fibrillation. A pooled analysis of five such trials in around 50,000 patients reported an incidence-rate ratio of about 1.37 versus placebo.^[14] Both REDUCE-IT and STRENGTH contributed to this signal at the 4 g/day dose.

The biomarker signal — pointing the other way. When the question is asked using physiological status rather than pharmacological dose, the relationship flips. In the UK Biobank, higher plasma omega-3 was associated with a lower incidence of new AFib (hazard ratio ~0.89 per interquartile range increase), and self-reported over-the-counter fish-oil use in the general population showed no increased AFib risk after adjustment for age and other confounders.^[15]

The reconciliation most consistent with the data: chronic, moderate dietary or supplemental intake that gradually raises membrane EPA/DHA appears to be protective against atrial remodelling. Acute high-dose loading in older, already-diseased patients may transiently destabilize cardiac membrane electrophysiology and tip a small number of susceptible patients into atrial fibrillation. The relevant clinical lesson is dose discipline: 1–2 g/day routinely is associated with the protective biomarker signal; 4 g/day is prescription-territory and carries a small AFib excess that has to be weighed against the (substantial) cardiovascular event reduction it also produces.

Cautions

• Atrial fibrillation signal at high doses. As above — concentrated at 4 g/day in older diseased populations. Standard 1–2 g/day doses are not implicated.
• Bleeding. High-dose omega-3 lengthens bleeding time modestly. Surgical guidelines vary; many clinicians advise stopping for about a week before elective surgery.
• Drug interactions. Anticoagulants and antiplatelet drugs can have additive bleeding effects with very high omega-3 doses.
• Pregnancy / lactation. DHA is important — the requirement actually rises — but choose products with verified low contaminant panels.

What to skip

• ALA-only supplements (flaxseed oil, chia oil) — ALA converts to EPA/DHA at single-digit-percent rates and yields negligible DHA. Useful as food, not as a substitute for marine omega-3.
• Generic "fish oil" without a third-party oxidation certificate. Rancid product is common, especially on unrefrigerated retail shelves, and undoes most of the point of supplementing.
• Krill oil at premium prices — the absorption advantage doesn't justify the per-gram cost of EPA+DHA delivered for most people.
• Flavoured, gummy, or chewable omega-3 for adults — the freshness data on these formats is consistently the worst, and the per-capsule EPA+DHA load is low.

Further reading

• Bhatt DL et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). NEJM 2019.^[16]
• Nicholls SJ et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events (STRENGTH). JAMA 2020.^[17]
• Manson JE et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (VITAL). NEJM 2019.^[18]
• Harris WS et al. Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies (FORCE consortium). Nature Communications 2021.^[19]
• Bischoff-Ferrari HA et al. Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks (DO-HEALTH). Nature Aging 2024.^[20]
• Wang Y et al. Associations Between Plasma Omega-3 and Fish Oil Use With Risk of Atrial Fibrillation in the UK Biobank. J Am Heart Assoc 2025.^[21]
• Albert BB et al. Oxidation of marine omega-3 supplements and human health. Sci Rep 2015.^[22]

---